Galapagos Nv Share Price (NASDAQ: GLPG)

$31.44

▲

-0.97

(-2.99%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Galapagos Nv Stock chart to analyse performance

Galapagos Nv stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$31.44
Today's High:$31.83
$31.44
0.0%
Downside
Day's Volatility :1.23%
Upside
1.23%
52 Weeks Low:$22.36
52 Weeks High:$33.86
$31.44
28.88%
Downside
52 Weeks Volatility :33.96%
Upside
7.15%

Galapagos Nv Stock Returns

Period	Galapagos Nv	Sector (Health Care)	Index (Russel 2000)
3 Months	8.1%	3.6%	0.0%
6 Months	21.45%	-7.7%	0.0%
1 Year	8.4%	-12.6%	0.0%
3 Years	-36.95%	9.5%	-4.7%

Galapagos Nv Key Stats

Check Galapagos Nv key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$32.41
Open	$31.83
Today's High	$31.83
Today's Low	$31.44
Market Capitalization	$2.2B
Today's Volume	$114.3K
52 Week High	$33.86
52 Week Low	$22.36
Revenue TTM	$275.6M
EBITDA	$-279.4M
Earnings Per Share (EPS)	$-5.1
Profit Margin	-103.14%
Quarterly Earnings Growth YOY	0.75%
Return On Equity TTM	-10.39%

Stock Returns calculator for Galapagos Nv Stock including INR - Dollar returns

The Galapagos Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Galapagos Nv investment value today

Current value as on today

₹1,13,251

Returns

₹13,251

(+13.25%)

Returns from Galapagos Nv Stock

₹7,967 (+7.97%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Galapagos Nv Stock

-38%

Period: Jul 30, 2025 to Aug 29, 2025. Change in 30 Days versus previous period

Search interest for Galapagos Nv Stock from India on INDmoney has decreased by -38% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Galapagos Nv

Name
Holdings %
Name
Holdings %
TANG CAPITAL MANAGEMENT LLC
6.06%
Madison Avenue Partners, LP
2.85%
FMR Inc
2.36%
Prosight Management, LP
2.00%
EcoR1 Capital, LLC
1.57%
Finepoint Capital LP
1.00%

Analyst Recommendation on Galapagos Nv Stock

Rating

Trend

Hold

38%Buy

61%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Galapagos Nv(by analysts ranked 0 to 5 stars)

Galapagos Nv Share Price Target

What analysts predicted

Downside of 18.82%

Target:

$25.52

Current:

$31.44

Galapagos Nv share price target is $25.52, a slight Downside of 18.82% compared to current price of $31.44 as per analysts' prediction.

Galapagos Nv Stock Insights

Price Movement
In the last 1 month, GLPG stock has moved down by -5.1%
Decreasing Revenue
Revenue is down for the last 3 quarters, 75.49M → 65.28M (in $), with an average decrease of 6.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -153.40M → -105.74M (in $), with an average increase of 45.1% per quarter
GLPG vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 61.5%
GLPG vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 149.5%
Price to Sales
ForGLPG every $1 of sales, investors are willing to pay $151.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Galapagos Nv Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$939.0M	↑ 192.55%
Net Income	$166.5M	↓ 612.13%
Net Profit Margin	17.73%	↑ 27.86%

	FY20	Y/Y Change
Revenue	$581.5M	↓ 43.42%
Net Income	$-378.3M	↓ 307.55%
Net Profit Margin	-65.06%	↓ 82.79%

	FY21	Y/Y Change
Revenue	$548.1M	↑ 1.42%
Net Income	$-141.8M	↓ 59.67%
Net Profit Margin	-25.87%	↑ 39.19%

	FY22	Y/Y Change
Revenue	$534.7M	↑ 4.21%
Net Income	$-230.7M	↑ 73.81%
Net Profit Margin	-43.14%	↓ 17.27%

	FY23	Y/Y Change
Revenue	$261.5M	↓ 52.56%
Net Income	$230.9M	↓ 197.11%
Net Profit Margin	88.31%	↑ 131.45%

	FY24	Y/Y Change
Revenue	$288.4M	↑ 14.99%
Net Income	$77.5M	↓ 65.01%
Net Profit Margin	26.88%	↓ 61.43%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$67.9M	↓ 129.85%
Net Income	$98.1M	↓ 42.74%
Net Profit Margin	144.51%	↑ 219.85%

	Q2 FY24	Q/Q Change
Revenue	$83.8M	↑ 24.73%
Net Income	$9.7M	↓ 90.04%
Net Profit Margin	11.54%	↓ 132.97%

	Q3 FY24	Q/Q Change
Revenue	$66.5M	↓ 23.15%
Net Income	$-56.0M	↓ 661.27%
Net Profit Margin	-84.26%	↓ 95.8%

	Q4 FY24	Q/Q Change
Revenue	$79.0M	↑ 26.14%
Net Income	$26.5M	↓ 150.18%
Net Profit Margin	33.52%	↑ 117.78%

	Q1 FY25	Q/Q Change
Revenue	$81.1M	↓ 0.69%
Net Income	$-165.9M	↓ 706.17%
Net Profit Margin	-204.6%	↓ 238.12%

	Q2 FY25	Q/Q Change
Revenue	$65.3M	↓ 12.92%
Net Income	$-105.7M	↓ 31.07%
Net Profit Margin	-161.97%	↑ 42.63%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$464.1M	↓ 1326.99%

	FY20	Y/Y Change
Profit	$-55.5M	↓ 110.92%

	FY21	Y/Y Change
Profit	$546.3M	↓ 1159.36%

	FY22	Y/Y Change
Profit	$521.9M	↑ 2.07%

	FY23	Y/Y Change
Profit	$222.3M	↓ 58.69%

	FY24	Y/Y Change
Profit	$-99.0M	↓ 146.47%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$65.1M	↓ 120.4%

	Q2 FY24	Q/Q Change
Profit	$66.0M	↑ 2.39%

	Q3 FY24	Q/Q Change
Profit	$66.4M	↓ 2.42%

	Q4 FY24	Q/Q Change
Profit	$-39.2M	↓ 162.57%

	Q1 FY25	Q/Q Change
Profit	$66.2M	↓ 263.62%

	Q2 FY25	Q/Q Change
Profit	$60.6M	↓ 1.09%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$3.6B	↓ 2352.2%
Investing Cash Flow	$-4.2B	↑ 23556.28%
Financing Cash Flow	$1.5B	↑ 364.0%

	FY20	Y/Y Change
Operating Cash Flow	$-519.8M	↓ 113.32%
Investing Cash Flow	$921.1M	↓ 120.12%
Financing Cash Flow	$26.8M	↓ 98.35%

	FY21	Y/Y Change
Operating Cash Flow	$-569.6M	↑ 17.9%
Investing Cash Flow	$611.8M	↓ 28.53%
Financing Cash Flow	$-4.4M	↓ 117.59%

	FY22	Y/Y Change
Operating Cash Flow	$-529.7M	↓ 0.65%
Investing Cash Flow	$-1.3B	↓ 330.12%
Financing Cash Flow	$-1.6M	↓ 61.64%

	FY23	Y/Y Change
Operating Cash Flow	$-442.9M	↓ 18.89%
Investing Cash Flow	$77.7M	↓ 105.72%
Financing Cash Flow	$-5.5M	↑ 236.31%

	FY24	Y/Y Change
Operating Cash Flow	$-334.8M	↓ 21.17%
Investing Cash Flow	$230.8M	↑ 209.89%
Financing Cash Flow	$-5.2M	↓ 1.54%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-128.0M	↑ 76.14%
Investing Cash Flow	$27.2M	↓ 67.27%
Financing Cash Flow	$-1.3M	↓ 1.93%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-66.2M	↓ 47.76%
Investing Cash Flow	$65.8M	↑ 144.31%
Financing Cash Flow	$-1.1M	↓ 8.9%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-79.7M	↑ 16.68%
Investing Cash Flow	$62.8M	↓ 7.44%
Financing Cash Flow	$-1.2M	↑ 2.26%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-62.1M	↓ 17.3%
Investing Cash Flow	$71.5M	↑ 20.86%
Financing Cash Flow	$-1.7M	↑ 47.43%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-41.8M	↓ 34.97%
Investing Cash Flow	$91.6M	↑ 23.97%
Financing Cash Flow	$-1.1M	↓ 36.97%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-108.8M	↑ 181.76%
Investing Cash Flow	$74.7M	↓ 11.84%
Financing Cash Flow	$-600.0K	↓ 40.65%

Galapagos Nv Technicals Summary

Sell

Neutral

Buy

Galapagos Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Galapagos Nv Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Galapagos Nv	-3.82%	21.45%	8.4%	-36.95%	-76.3%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.98%	-0.05%	-6.32%
Beone Medicines Ltd	1.77%	24.81%	59.79%	78.52%	26.86%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-21.18%	38.72%	40.03%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	69.91%	115.96%	236.5%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Galapagos Nv	50.85	NA	0.0	-3.85	-0.1	-0.05	NA	40.12
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Galapagos Nv	Hold	$2.2B	-76.3%	50.85	-103.14%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-6.32%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	26.86%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	40.03%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	236.5%	NA	-12.96%

About Galapagos Nv

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Organization	Galapagos Nv
Employees	558
CEO	Mr. Henry Gosebruch
Industry	Health Technology

Key Management of Galapagos Nv

Name	Title
Mr. Henry Gosebruch	CEO & Executive Director
Mr. Aaron L. Cox	Chief Financial Officer
Ms. Valeria Cnossen	Executive VP & General Counsel
Marieke Vermeersch	Head of Corporate Communication
Ms. Annelies Missotten	Executive VP & Chief Human Resources Officer
Ms. Ellen Van Der Aar	Head of Development
Mr. Philippe Alen M.B.A., Ph.D., Pharm.D.	Senior VP & Head of Business Development
Ms. Alice Dietrich	Head of Medical Affairs
Mr. Patrik Ringblom	Head of Strategy & US Lead
Dr. Jeevan Shetty	Head of Clinical Development Oncology

Important FAQs about investing in GLPG Stock from India :

What is Galapagos Nv share price today?

Galapagos Nv share price today is $31.44 as on August 30, 2025 at 1:29 am IST at the close of the market. Galapagos Nv share today touched a day high of $31.83 and a low of $31.44.

What is the 52 week high and 52 week low for Galapagos Nv share?

Galapagos Nv share touched a 52 week high of $33.86 and a 52 week low of $22.36. Galapagos Nv stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $31.44, lower by 7.15% versus the 52 week high.

How to invest in Galapagos Nv Stock (GLPG) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Galapagos Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Galapagos Nv Shares that will get you 0.0477 shares as per Galapagos Nv share price of $31.44 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Galapagos Nv Stock (GLPG) from India?

Indian investors can start investing in Galapagos Nv (GLPG) shares with as little as ₹88.286 or $1 (as of August 30, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Galapagos Nv stock (as per the Rupee-Dollar exchange rate as on August 30, 2025). Based on Galapagos Nv share’s latest price of $31.44 as on August 30, 2025 at 1:29 am IST, you will get 0.3181 shares of Galapagos Nv. Learn more about fractional shares .

What are the returns that Galapagos Nv has given to Indian investors in the last 5 years?

Galapagos Nv stock has given -76.3% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?